Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL NASDAQ:FHTX NASDAQ:PLRX NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$7.02+0.3%$5.64$3.79▼$14.60$350.72M-0.911.10 million shs597,820 shsFHTXFoghorn Therapeutics$6.19$4.91$2.94▼$10.25$345.04M3.05149,551 shs82,023 shsPLRXPliant Therapeutics$1.57-1.3%$1.38$1.10▼$16.10$97.60M1.31.84 million shs560,458 shsTNXPTonix Pharmaceuticals$49.72+11.2%$37.11$6.76▼$130.00$329.01M2.051.09 million shs1.94 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics+0.57%+1.16%+44.33%+40.56%+10.06%FHTXFoghorn Therapeutics-4.33%+1.48%+27.10%+41.97%-0.96%PLRXPliant Therapeutics+0.63%+11.97%+22.31%+8.90%-87.47%TNXPTonix Pharmaceuticals-1.76%-5.23%+25.37%+150.95%-15.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.0849 of 5 stars3.61.00.00.02.21.70.6FHTXFoghorn Therapeutics2.2035 of 5 stars3.60.00.00.03.51.70.6PLRXPliant Therapeutics4.3414 of 5 stars3.05.00.04.72.21.70.6TNXPTonix Pharmaceuticals2.599 of 5 stars3.52.00.00.01.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.20Buy$22.00213.39% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.1395.88% UpsidePLRXPliant Therapeutics 2.00Hold$13.31747.93% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.0040.79% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, TNXP, FHTX, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025CADLCandel TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,930.85N/AN/A$1.41 per share4.98FHTXFoghorn Therapeutics$22.60M15.27N/AN/A($0.82) per share-7.55PLRXPliant Therapeutics$1.58M61.00N/AN/A$5.00 per share0.31TNXPTonix Pharmaceuticals$10.09M36.27N/AN/A$31.82 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)FHTXFoghorn Therapeutics-$86.62M-$1.360.00N/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)PLRXPliant Therapeutics-$210.30M-$3.610.00N/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.610.00N/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest PLRX, TNXP, FHTX, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q1 2025TNXPTonix Pharmaceuticals-$6.71N/AN/AN/A$2.60 millionN/A8/14/2025Q2 2025FHTXFoghorn Therapeutics-$0.32N/AN/AN/AN/AN/A8/12/2025Q2 2025CADLCandel Therapeutics-$0.17N/AN/AN/AN/AN/A8/6/2025Q2 2025PLRXPliant Therapeutics-$0.62N/AN/AN/AN/AN/A5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.014.644.64FHTXFoghorn TherapeuticsN/A3.163.16PLRXPliant TherapeuticsN/A11.0311.03TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%FHTXFoghorn Therapeutics61.55%PLRXPliant Therapeutics97.30%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%FHTXFoghorn Therapeutics7.58%PLRXPliant Therapeutics8.00%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableFHTXFoghorn Therapeutics12055.74 million51.52 millionOptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionablePLRX, TNXP, FHTX, and CADL HeadlinesRecent News About These CompaniesTonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by FibromyalgiaJuly 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?July 19, 2025 | marketbeat.comTonix Pharma Plans Sales Force for TNX-102 SLJuly 16, 2025 | tipranks.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.8% - Time to Sell?July 11, 2025 | marketbeat.comTonix up after peer reviewed data for pain therapy and new data for mpox vaccineJuly 10, 2025 | msn.comTonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine ResultsJuly 10, 2025 | msn.comTonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data ReleaseJuly 10, 2025 | gurufocus.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?July 10, 2025 | marketbeat.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock NewsJuly 10, 2025 | gurufocus.comTonix Pharma Unveils Promising TNX-801 Vaccine FindingsJuly 10, 2025 | tipranks.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025July 10, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's WhyJuly 9, 2025 | marketbeat.comTonix Pharma Publishes Phase 3 Trial ResultsJuly 9, 2025 | tipranks.comTonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia ManagementJuly 9, 2025 | quiverquant.comQTonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain MedicineJuly 9, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's WhyJuly 7, 2025 | marketbeat.comTonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against MonkeypoxJuly 7, 2025 | quiverquant.comQTonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025July 7, 2025 | globenewswire.comTNXP Tonix Pharmaceuticals Holding Corp. - Seeking AlphaJuly 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRX, TNXP, FHTX, and CADL Company DescriptionsCandel Therapeutics NASDAQ:CADL$7.02 +0.02 (+0.29%) Closing price 04:00 PM EasternExtended Trading$6.98 -0.04 (-0.51%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Foghorn Therapeutics NASDAQ:FHTX$6.19 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.23 +0.04 (+0.65%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Pliant Therapeutics NASDAQ:PLRX$1.57 -0.02 (-1.26%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Tonix Pharmaceuticals NASDAQ:TNXP$49.72 +5.00 (+11.18%) Closing price 04:00 PM EasternExtended Trading$49.28 -0.45 (-0.90%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
